Globus Medical Inc banner

Globus Medical Inc
XBER:GM0N

Watchlist Manager
Globus Medical Inc Logo
Globus Medical Inc
XBER:GM0N
Watchlist
Price: 74.5 EUR Market Closed
Market Cap: €10.1B

Wall St Price Targets

GM0N Price Targets Summary
Globus Medical Inc

Wall Street analysts forecast GM0N stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GM0N is 102.35 EUR with a low forecast of 81.71 EUR and a high forecast of 119.11 EUR.

Lowest Forecast
Price Target
81.71 EUR
10% Upside
Average Forecast
Price Target
102.35 EUR
37% Upside
Highest Forecast
Price Target
119.11 EUR
60% Upside
Globus Medical Inc Competitors:
Price Targets
TEL
TE Connectivity Ltd
34% Upside
XPEL
Xpel Inc
9% Upside
UNFI
United Natural Foods Inc
13% Upside

Revenue
Forecast

17% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
17% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 3 years is 8%.

Gross Profit
Forecast

15% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
15% / Year
Past Growth
10% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 10%.

Operating Income
Forecast

13% / Year
Past Growth
23% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
13% / Year
Past Growth
23% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 23%.

Pre-Tax Income
Forecast

14% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss
14% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-11%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is 19%.

Net Income
Forecast

17% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss
17% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-12%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 17%. The projected CAGR for the next 3 years is 14%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GM0N's stock price target?
Price Target
102.35 EUR

According to Wall Street analysts, the average 1-year price target for GM0N is 102.35 EUR with a low forecast of 81.71 EUR and a high forecast of 119.11 EUR.

What is the Revenue forecast for Globus Medical Inc?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 3 years is 8%.

What is the Gross Profit forecast for Globus Medical Inc?
Projected CAGR
10%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 10%.

What is the Operating Income forecast for Globus Medical Inc?
Projected CAGR
23%

Over the last 13 years, the compound annual growth rate for Operating Income has been 13%. The projected CAGR for the next 3 years is 23%.

What is the Pre-Tax Income forecast for Globus Medical Inc?
Projected CAGR
19%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 14%. The projected CAGR for the next 3 years is 19%.

What is the Net Income forecast for Globus Medical Inc?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Net Income has been 17%. The projected CAGR for the next 3 years is 14%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett